down arrow

PharmaCyte Biotech, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US71715X2036
USD
1.21
0.46 (61.96%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.901.49

52 Week

0.631.90
Valuation
Technical
Day's Volume

CASH

112.31 M

Shareholding (Jan 2025)

FII

3.49%

Held by 7 FIIs

DII

90.69%

Held by 6 DIIs

Promoter

0.00%

How big is PharmaCyte Biotech, Inc.?

22-Jun-2025

As of Jun 18, PharmaCyte Biotech, Inc. has a market capitalization of 7.28 million, with net sales of 0.00 million and a net profit of 20.25 million over the latest four quarters. The company reported shareholder's funds of 39.51 million and total assets of 59.90 million as of Apr 24.

Market Cap: As of Jun 18, PharmaCyte Biotech, Inc. has a market capitalization of 7.28 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, PharmaCyte Biotech, Inc. reported net sales of 0.00 million and a net profit of 20.25 million.<BR><BR>Balance Sheet Snapshot: As of Apr 24, the company reported shareholder's funds of 39.51 million and total assets of 59.90 million.

Read More

What does PharmaCyte Biotech, Inc. do?

22-Jun-2025

PharmaCyte Biotech, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit of -$3 million and a market cap of $7.28 million. Key metrics include a P/E ratio of 0.00 and a return on equity of 43.35%.

Overview: <BR>PharmaCyte Biotech, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Jan 2025) <BR>Market Cap: USD 7.28 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 0.00 <BR>Debt Equity: -0.42 <BR>Return on Equity: 43.35% <BR>Price to Book: 0.18 <BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is PharmaCyte Biotech, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, PharmaCyte Biotech, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and price-to-book ratio of 5.6, especially when compared to peers like Amgen and Gilead, alongside its recent underperformance against the Sensex.

As of 3 October 2023, PharmaCyte Biotech, Inc. has moved from fair to overvalued. The company currently exhibits a price-to-earnings ratio of 45.2, a price-to-book ratio of 5.6, and a debt-to-equity ratio of 0.1, which indicates a relatively high valuation compared to its earnings and assets. When compared to peers such as Amgen Inc. with a P/E ratio of 22.5 and Gilead Sciences, Inc. at 11.8, PharmaCyte's valuation appears excessive.<BR><BR>Overall, the analysis suggests that PharmaCyte Biotech is overvalued given its high ratios in relation to industry standards. This valuation is further supported by the company's recent stock performance, which has lagged behind the Sensex, reinforcing the notion that the current market price may not accurately reflect its underlying value.

Read More

Is PharmaCyte Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, PharmaCyte Biotech, Inc. shows a neutral technical trend with mixed indicators, including mildly bullish MACD signals, but has significantly underperformed the S&P 500 with year-to-date and one-year returns of -38.17% and -49.70%, respectively.

As of 11 September 2025, the technical trend for PharmaCyte Biotech, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with a mix of indicators showing both bullish and bearish signals. The MACD is mildly bullish on both the weekly and monthly time frames, while the KST is mildly bullish weekly but bearish monthly. The moving averages indicate a mildly bearish stance on the daily chart, and Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. <BR><BR>Despite the mildly bullish indicators, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -38.17% versus the S&P 500's 12.22%, and a one-year return of -49.70% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8 Million ()

stock-summary
P/E

0.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

35.52%

stock-summary
Price to Book

0.15

Revenue and Profits:
Net Sales:
(Quarterly Results - Apr 2025)
Net Profit:
12 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.86%
0%
25.86%
6 Months
10.0%
0%
10.0%
1 Year
-27.54%
0%
-27.54%
2 Years
-47.16%
0%
-47.16%
3 Years
-58.84%
0%
-58.84%
4 Years
-50.0%
0%
-50.0%
5 Years
-86.99%
0%
-86.99%

PharmaCyte Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is PharmaCyte Biotech, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for PharmaCyte Biotech, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with a mix of indicators showing both bullish and bearish signals. The MACD is mildly bullish on both the weekly and monthly time frames, while the KST is mildly bullish weekly but bearish monthly. The moving averages indicate a mildly bearish stance on the daily chart, and Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. Despite the mildly bullish indicators, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -38.17% versus the S&P 500's 12.22%, and a one-year return of -49.70% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-3.05%
EBIT to Interest (avg)
-6.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.55%
ROCE (avg)
0
ROE (avg)
9.07%
Valuation key factors
Factor
Value
P/E Ratio
0
Industry P/E
Price to Book Value
0.17
EV to EBIT
2.17
EV to EBITDA
2.17
EV to Capital Employed
-0.42
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
43.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jan 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (5.82%)

Foreign Institutions

Held by 7 Foreign Institutions (3.49%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 800.00% vs 1,400.00% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-1.20",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.60",
          "val2": "3.10",
          "chgp": "306.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11.70",
          "val2": "1.30",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is 10,133.33% vs 106.98% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-6.50",
          "chgp": "32.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.20",
          "val2": "4.80",
          "chgp": "154.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "30.70",
          "val2": "0.30",
          "chgp": "10,133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - YoYstock-summary
Apr'25
Apr'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.00
-1.20
16.67%
Interest
0.00
0.00
Exceptional Items
12.60
3.10
306.45%
Consolidate Net Profit
11.70
1.30
800.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is 800.00% vs 1,400.00% in Apr 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Apr'25stock-summary
Apr'25
Apr'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.40
-6.50
32.31%
Interest
0.00
0.00
Exceptional Items
12.20
4.80
154.17%
Consolidate Net Profit
30.70
0.30
10,133.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2025 is 10,133.33% vs 106.98% in Apr 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About PharmaCyte Biotech, Inc. stock-summary
stock-summary
PharmaCyte Biotech, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."